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Abstract
Although the majority of lung adenocarcinomas show mixed pattern, only the predominant component is taken into account
according to the novel classification. We evaluated the proportion of different patterns and their impact on overall survival
(OS) and disease-free survival (DFS). Patterns were recorded according to predominance and their proportions were rated
and calculated by objective area measuring on digitalized, annotated slides of resected stage I lung adenocarcinomas.
Spearman’s rank correlation, Kaplan-Meier models and the log rank test were used for statistical evaluation. Two hundred
forty-three stage I adenocarcinoma were included. Lepidic pattern is more frequent in tumours without recurrence (20 vs.
8%), and lepidic predominant tumours have favourable prognosis (OS 90.5%, DFS 89.4%), but proportions above 25% are
not associated with improving outcome. Solid and micropapillary patterns are more frequent in patients with recurrence (48
vs. 5% and 13 vs. 4%) and predominance of each one is associated with unfavourable prognosis (OS 64.1%, DFS 56.3% and
OS 28.1%, DFS 28.1%, respectively). Above 25%, a growing proportion of solid or micropapillary pattern is not associated
with worsening prognosis. In contrast, tumours having micropapillary pattern as secondly predominant form a different
intermediate group (OS 51.1%, DFS 57.8%). Our study was based on measured area of each growth pattern on all available
slides digitalized. This is the most precise way of determining the size of each component from the material available. We
propose using predominant and secondly predominant patterns for prognostic purposes, particularly in tumours having
solid or micropapillary patterns.
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Introduction
The new classification of lung cancers was introduced by the
World Heal th Organizat ion (WHO) in 2015 [1] .
Adenocarcinoma is the most frequent histological subtype
among non-small cell carcinomas. Most cases of adenocarci-
noma are neoplasms with mixed architecture. They should be
subclassified according to the predominant growth pattern,
after identification and quantification of all histological pat-
terns in the tumour in 5% increments [1, 2]. Examples of the
different growth patterns are demonstrated in Supplementary
Fig. 1.
Recent studies have focused on predominant growth pat-
terns and their impact on survival. It is well documented that
lepidic predominant carcinomas have better outcome [3],
while solid and micropapillary predominant carcinomas have
an unfavourable prognosis [3–7]. These results have validated
the novel classification of lung adenocarcinomas. However,
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many lung adenocarcinomas show mixed-subtype patterns
with two or more different growth patterns, and the impact
of non-predominant growth patterns on survival is
controversial.
Three growth patterns of invasive adenocarcinomas have
been investigated recently, namely the lepidic, the solid and
micropapillary patterns. Higher proportion of lepidic compo-
nent is usually associated with better prognosis [8]. Pure le-
pidic carcinoma is defined as in situ adenocarcinoma with
100% overall survival (OS) and disease-free survival (DFS).
The rates of OS and DFS are similarly excellent in case of
minimally invasive adenocarcinoma which is a lepidic pre-
dominant tumour with invasive focus less than 5 mm [3].
Invasive, lepidic predominant carcinomas belong to low-
grade tumours according to the architectural grade, due to
their favourable prognosis [7].
A higher proportion of solid or micropapillary pattern re-
fers to worse prognosis. Local recurrence, nodal involvement
and distant metastases are more frequent among these neo-
plasms [9]. Some authors have found that even 1% [10–13]
or 5% [5, 14–18] of these components may cause an
unfavourable outcome. In contrast, Roh and coworkers [19]
could not confirm that 5% of micropapillary component re-
sults in worse OS. Similarly, Sumiyoshi et al. found that the
mean percentages of micropapillary pattern showed no signif-
icant differences in the recurrent (20.4%) and non-recurrent
(18.3%) groups [20].
Beneath the evaluation of proportions of components, pre-
dominant and secondary predominant growth patterns can be
investigated, as well. Zhao and coworkers have found that
acinar/papillary carcinomas having secondary predominant
solid or micropapillary patterns show worse prognosis than
acinary/papillary carcinomas without secondary solid or
micropapillary components [21].
Our aim was to analyse the predominant and the secondary
predominant components and the proportions of different
growth patterns, namely lepidic, acinar, papillary, solid,
micropapillary and cribriform, in stage I lung adenocarcinoma
and their influence on OS and DFS. To reach this aim, we
decided to use an objective measurement, i.e. the best approx-
imation of areas involved by each pattern available for the
cases.
Materials and methods
Haematoxylin-eosin slides of consecutive patients having pul-
monary adenocarcinoma in stage I according the 8th Edition
of TNMClassification [22] were analysed in our retrospective
cohort study. The patients were operated on between 2004 and
2013 at the Division of Thoracic Surgery, Department of
Surgery, University of Szeged. The following cases were ex-
cluded: patients having multicentric, metachronous or
metastatic tumours, or variants of adenocarcinoma, namely
invasive mucinous, mixed invasive mucinous/non-mucinous,
colloid, foetal, enteric and pleomorphic/sarcomatoid, and
those having lung cancer surgery in the preceding 2 years,
positive surgical margins, perioperative death, vascular inva-
sion and lack of immunohistochemical phenotyping. For all
cases included, mucin staining and immunohistochemistry
were applied in the routine diagnostic process. Mucin produc-
tion and TTF-1 positivity were considered as evidence in sup-
port of a primary pulmonary adenocarcinoma for non-small
cell lung cancer cases. For TTF-1-negative tumours, further
immunohistochemical results have been considered to rule out
squamous cell carcinoma (p40 negativity) and metastatic car-
cinoma (different markers for different primaries).
Clinical data, including gender, age, tumour localization,
type of surgery, smoking habits, KRAS and EGFR mutation
status and site of recurrence, and follow-up data were obtained
from medical charts. Stage I was defined by the combination
of tumour size and nodal status in addition to clinical data
about the lack of distant metastasis. In all cases, lymphade-
nectomy was part of the operation and the lymph nodes were
examined histologically. The follow-up of patients consisted
of three-monthly physical examination, chest x-ray examina-
tion and abdominal ultrasonography evaluation in the first
2 years, then six monthly until the fifth year. Chest computer
tomography (CT) was performed every 6 months for the first
2 years, then 6 or 12 monthly depending on the patient, until
the fifth year. In case of any suspicion of progression, chest
CT and abdominal ultrasonography were included. The
follow-up period ended on the 31th August 2017.
All available tumour containing slides were digitalized by a
Pannoramic 250 scanner (3DHistec, Budapest). As one sec-
tion was taken from each centimetre of the largest tumour
dimension, the number of slides digitalized was influenced
by tumour size. The Case Viewer software (3DHistec,
Budapest) was utilised for evaluating the cases.
A previous study [7] was based on the evaluation of glass
slides; the proportions of growth patterns and the predominant
component were estimated by two pathologists (TL, ZT), and
consensus was always reached. We also used these results for
the assessment of reproducibility between glass slide-based
estimation of areas and digital slide-based estimation of the
same areas. In the present study, we used digitalized slides. In
the first step, the proportions of growth patterns were estimat-
ed in 5% increments, and the predominant, secondly and
thirdly predominant components were determined with naked
eye evaluation. In the second step, the different patterns of the
entire tumour were annotated and their areas were measured in
square millimetre (Fig. 1). The proportions of each component
were calculated from the measured areas. In the third step, the
predominant and secondly predominant patterns were re-
evaluated in one third of the cases after a time period of min-
imum 2 weeks. The patterns were re-annotated for assessing
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intra-observer (ZT) variability. All available tumour slides
were used for all the listed evaluations.
Statistical methods
Statistical models were based on the calculated proportions of
the components (second step evaluation mentioned above).
Spearman’s rank correlation was used to investigate intra-
observer variability. Five-year OS and DFS estimates and
mean survival times with their 95% confidence intervals
(95% CI) for OS and DFS were assessed using Kaplan-Meier
estimates. The log rank test was used for pairwise compari-
sons. All statistical tests were two-sided, and p < 0.05 values
were considered statistically significant. We utilised the SPSS
Statistics software (IBM, SSPS 22.0, Armonk, NY, USA).
This retrospective study was approved by the institutional
ethical committee of the Albert Szent-Györgyi Clinical Centre
of the University of Szeged (ethical approval: 168/2016-
SZTE).
Results
Altogether, 327 patients matched the inclusion criteria de-
scribed in the BMaterials and methods^ section. Clinical
follow-up data were missing in 35 cases of surviving and in
31 cases of deceased patients. Slides were not available in 18
cases. After exclusion of patients with missing data or slides,
243 cases remained for this retrospective analysis, with 141
cases in stage IA1–3 and 102 cases in stage IB.
Median age of the patients was 62.3 years (range 33–85).
No gender predominance was observed (female 50.7% vs.
male 49.3%) in stage I.Most patients had complete lobectomy
(lobectomy 90.1% vs. sublobar resection 9.9%).
Supplementary Table 1 displays the most important clinico-
pathological data.
With all available haematoxylin-eosin-stained slides digi-
talized and evaluated, the median number of slides per patient
was 3 (range 2–5). Although the statistical results described
below were based on the calculated proportions of the com-
ponents, the results, not displayed in this study, were similar if
the proportions were determined with naked eye (see also
below and Supplementary Table 2).
In Table 1, the different growth patterns were recorded in
all cases as predominant, secondly predominant, thirdly pre-
dominant or absent and associated with 5-year OS and DFS
estimates. Themedian follow-up was 61.5months (range 1.5–
175.3 months). As listed under the table, significant differ-
ences in survival rates were found in association with propor-
tions of lepidic pattern (better survival) and proportions of
micropapillary or solid patterns (worse survival).
Fig. 1 Examples of annotations
of digitalized slides (A: HE, 0.5×;
B: HE, 1.5×; 1 (blue): whole
tumour, 2 and 3 (red): minor
components of tumour)
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Table 2 demonstrates the OS and DFS estimates of growth
patterns grouped into five groups, namely 0, ≤ 25, 26–50, 51–
75 and ≥ 75%. Significant differences were observed between
various subgroups of lepidic, solid andmicropapillary patterns
(see Table 3).
The OS and DFS rates of growth patterns classified as ≥ 5
and < 5% and ≥ 1 and < 1% are displayed in Table 4. With the
5% cut-off point, significant differences in survival were ob-
served in lepidic, solid and micropapillary patterns, and with
the 1% cut-off point in lepidic and solid patterns.
There was no recurrence in 151 cases (62.1%). Among
these cases, the predominant patterns were the following: le-
pidic (n = 40), acinar (n = 22), papillary (n = 25), solid (n =
54), micropapillary (n = 5) and cribriform (n = 5).
Recurrence was diagnosed in 92 cases including lepidic (n =
8), acinar (n = 14), papillary (n = 10), solid (n = 46),
micropapillary (n = 11) and cribriform (n = 3) carcinomas.
The rate of recurrence was low in lepidic carcinoma
(16.6%); intermediate in acinar (38.8%), papillary (28.5%)
and cribriform carcinomas (37.5%); and high in solid (46%)
and micropapillary carcinomas (68.7%). Systemic dissemina-
tion was detected in 59 patients including lepidic (n = 5), ac-
inar (n = 8), papillary (n = 6), solid (n = 30), micropapillary
(n = 9) and cribriform (n = 1) carcinomas. In the non-
recurrent group, the average proportion of lepidic, solid and
micropapillary patterns were 20, 4 and 5%, respectively,
whereas in the recurrent group, these rates were 8, 48 and
13%, respectively. The proportions of other patterns were
close to equal in the recurrent and non-recurrent groups.
Besides the morphological evaluation, KRAS and EGFR
mutation profiles were analysed in cases with available data
(Supplementary Table 3). Sixty-seven percent of KRAS mu-
tations were found in high-grade tumours, especially in solid
neoplasms, while most EGFR activating mutations (88.8%)
were in low–intermediate-grade tumours, like lepidic, acinar
and papillary carcinomas.
In this study, we used naked eye estimation and area mea-
suring for determining the proportions of patterns. As con-
cerns the variability of these methods for the determination
of the area of different growth patterns, the opinion agreement
was the highest in lepidic, acinar and solid patterns, while
papillary, micropapillary and cribriform patterns showed
higher variability. In all but one case, the concordance was
significant, i.e. there were no relevant differences between
the estimated and the calculated proportions of growth pat-
terns (Supplementary Table 2).
Discussion
The new WHO classification of lung adenocarcinomas fol-
lows the recommendations of the International Association
for the Study of Lung Cancer (IASLC), the American Ta
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Thoracic Society (ATS) and the European Respiratory Society
(ERS). Although the majority of these carcinomas are mixed,
the classification takes only the predominant pattern into con-
sideration. Recent studies have shown that secondly predom-
inant patterns or even a small proportion of some patterns can
alter prognosis.
Lepidic growth pattern is defined by neoplastic cells grow-
ing along the pre-existing alveolar walls. This pattern is the
first morphologic sign of carcinogenesis, and if the tumour
shows only this pattern, it is called in situ carcinoma and has
an excellent prognosis [3]. The lepidic pattern may be associ-
ated with other patterns in mixed tumours. Lepidic carcinoma
is an invasive tumour with lepidic predominant component
and is associated with favourable outcome; therefore, it may
be proposed that the more lepidic pattern, the better the prog-
nosis. Mäkinen and coworkers have proven in their series that
carcinomas with non-predominant lepidic pattern have more
favourable outcome [8]. Although a significant difference was
seen between OS and DFS of adenocarcinomas without lepid-
ic component and tumours having ≥1 or ≥ 5% lepidic compo-
nent, there was no difference in OS and DFS between tumours
without lepidic component and tumours having ≤ 25, 25–50
or 51–75% lepidic areas. Our results confirm the evidence that
lepidic predominant carcinoma has a favourable prognosis,
but there was no difference in OS or DFS between tumours
with secondly predominant lepidic component and tumours
without lepidic component. A difference was found between
the mean proportion of lepidic component of tumours with
recurrence (8%) and those without recurrence (20%).
Solid pattern lacking glandular differentiation is a feature
of high-grade lung adenocarcinomas. Recent studies have
shown that solid predominant adenocarcinoma has a poor out-
come [3, 23] and secondary predominant solid pattern or even
a small amount of solid component (≥ 5 or ≥ 1%) may worsen
the prognosis [12, 18, 21]. A significant difference was ob-
served between OS and DFS of tumours having ≥ 5 or ≥ 1%
solid component and those having less (Table 4). Similarly,
significant differences were found in OS and DFS between
various comparisons of tumours with solid component of 0, ≤
25, 26–50, 51–75 and > 75% (Table 3). Concerning a solid
predominant component, significant differences were found
between the OS and DFS estimates of solid predominant tu-
mours and neoplasms without solid features. Despite the
worsening tendency of OS and DFS with growing proportion
of the solid pattern (Table 1), there were no differences be-
tween tumours having secondly or thirdly predominant solid
component and tumours without solid pattern. The mean pro-
portion of solid pattern in tumours with recurrence was 48%,
contrasting with the 5% in adenocarcinomas without
recurrence.
The micropapillary pattern has been incorporated in the
adenocarcinoma classification since 2015. Although, accord-
ing to the classification based on predominant pattern, it
would seems that only the greatest proportion of this pattern
matters, some studies [5, 10–12, 14–18, 20, 21, 24, 25] indi-
cated that even a minimal amount of micropapillary area is
associated with poor prognosis (Table 5).
Kamiya and coworkers have divided their patients into four
groups according to the proportion of micropapillary pattern
in the tumour: none (0%), focal (≤ 10%), moderate (≤ 50%)
and extensive (> 50%). They found that both OS and DFS
estimates were worse with the increase in the proportion of
the micropapillary component. The latter three groups had
significantly less favourable outcomes than tumours without
micropapillary pattern, but comparisons among the three latter
groups were not done [10]. Zhang et al. [26] have divided their
patients into four groups according to the extent of
micropapillary component, namely < 1, 1–5, 6–50 and >
51%. Their conclusion was similar to that of Kamiya et al.
Our results also parallel these two cited studies. The tumours
having more than 25% of micropapillary component formed a
uniform group according to OS and DFS estimates and dif-
fered from tumours having 0–25%micropapillary area. When
using the 5% cut-off for micropapillary component, a signif-
icant difference was observed in survival in comparison with
tumours with no micropapillary component, while at 1% cut-
off point, such a difference was not found. In contrast with
Sumiyoshi and coworkers [20], a difference was observed
between the groups of patients with and without recurrence:
the mean proportions of micropapillary pattern were 13 and
4%, respectively. In the present study, a significant difference
in survival was observed between tumours without
micropapillary pattern and micropapillary predominant tu-
mours. Similarly to Zhao and coworkers [21], tumours having
secondly predominant micropapillary pattern in our series
constituted a different group with prognosis between
micropapillary predominant carcinomas and tumours having
Table 3 Significant differences of proportions displayed in Table 2
Growth pattern Categories Log rank test
p (OS) p (DFS)
Lepidic 0 and > 75% 0.024 0.004
Lepidic < 25 and > 75% 0.05 0.04
Solid 0 and 25–50% 0.038 0.16
Solid 0 and > 75% 0.001 0.015
Solid < 25 and 25–50% 0.15 0.045
Solid < 25 and > 75% 0.032 0.028
Micropapillary 0 and 25–50% 0.034 0.039
Micropapillary 0 and 51–75% 0.002 0.006
Micropapillary 0 and > 75% 0.023 0.05
Micropapillary < 25 and 25–50% 0.22 0.035
Micropapillary < 25 and 51–75% 0.001 0.012
Micropapillary < 25 and > 75% 0.045 0.117
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thirdly predominant micropapillary component or lacking this
morphology.
By using 1 or 5% cut-off, significant differences were seen
between OS and DFS of tumours having lepidic, solid or
micropapillary component and tumours lacking them. After
division of mixed adenocarcinomas into four groups, namely
0, ≤ 25, 26–50, 51–75 and ≥ 75%, significant differences were
found between OS and DFS of tumours lacking solid or
micropapillary component and tumours having > 25% solid
or micropapillary pattern. The latter three groups (26–50, 51–
75 and ≥ 75%) showed no difference in OS or DFS.
As our study showed, there is a broad spectrum of morpho-
logical intra-tumour heterogeneity in lung adenocarcinomas.
Interestingly, the invasive tumours having only one compo-
nent had a more unfavourable prognosis, than neoplasms hav-
ing mixed pattern (Supplementary Table 4). This finding may
be explained by the fact that most tumours having one
component were solid tumours with poor outcome. Several
series have concluded that this morphological heterogeneity
is paralleled by a more complex genetic heterogeneity, as well.
Instead of the traditional single-gene approaches, a huge num-
ber of genes can be analysed by next-generation sequencing.
This new method revealed that there are trunk mutations (e.g.
EGFR or KRAS), branching mutations (e.g. EZH2, PIK3CA
and p53) and private mutations (ABL1, ALK, BRAF, HER2,
etc.) according to the phylogenetic tree model of tumorigene-
sis. In keeping with earlier published results [27–31], we have
found that most EGFR activating mutations are present in the
low- or intermediate-grade tumours (lepidic, acinar and papil-
lary), while two thirds of KRASmutations are associated with
high-grade morphology (solid, micropapillary and cribri-
form). Pelosi and coworkers have demonstrated that one or
more branching mutations predicted poor overall survival,
independent from age, gender and stage. Finally, additional
Table 4 Five-year overall
survival (OS) and disease-free
survival estimates and mean
values of ≥ 5% or less and ≥ 1%
or less component with log rank
model results
Growth pattern ≥ 5% < 5% Log rank
n (%) OS (%) DFS (%) n (%) OS (%) DFS (%) p (OS) p (DFS)
Lepidic 61 (25) 81.4 77.8 182 (75) 72.1 61.6 0.04 0.021
Acinar 100 (42) 72.6 61.2 143 (58) 68.5 59.8 0.23 0.28
Papillary 104 (43) 78.6 71.4 139 (57) 73.4 67.4 0.54 0.12
Solid 127 (52) 67.5 58.7 116 (48) 80.2 71.7 0.012 0.005
Micropapillary 56 (23) 61.2 53 187 (77) 75.6 68.7 0.045 0.041
Cribriform 24 (10) 86.3 72 219 (90) 82 64.3 0.31 0.56
Mean OS 95%CI Mean OS 95%CI
Lower Upper Lower Upper
Lepidic 121.5 105.0 131.4 99.4 90.6 106.2
Acinar 105.2 91.1 112.2 101.2 93.7 115.6
Papillary 110.7 102.8 118.6 105.6 95.5 113.5
Solid 95.1 84.1 106.7 116.7 107.5 126.5
Micropapillary 94.5 81.5 105.1 114.5 105.2 124.4
Cribriform 102.6 89.5 110.0 101.1 91.8 118.7
Growth pattern ≥ 1% < 1% Log rank
n (%) OS (%) DFS (%) n (%) OS (%) DFS (%) p (OS) p (DFS)
Lepidic 64 (27) 82.2 78.9 179 (73) 71.7 61 0.037 0.008
Acinar 107 (44) 75.8 71 167 (56) 67.8 60 0.33 0.58
Papillary 114 (47) 80.3 74.1 129 (53) 71.5 65.2 0.27 0.078
Solid 138 (57) 66.7 60.2 105 (43) 82.5 72.7 0.045 0.005
Micropapillary 72 (30) 69.4 56.6 171 (70) 74.1 68.6 0.95 0.11
Cribriform 31 (13) 82.5 71.9 212 (87) 72.4 64 0.42 0.49
Mean OS 95%CI Mean OS 95%CI
Lower Upper Lower Upper
Lepidic 119.8 106.5 131.6 98.7 88.8 107.7
Acinar 104.9 92.4 116.6 95.4 82.2 106.5
Papillary 115.8 106.2 125.4 108.7 95.4 115.7
Solid 89.4 75.6 101.2 107.6 98.6 116.9
Micropapillary 105.4 91.1 119.0 105.8 95.6 114.3
Cribriform 103.5 82.4 125.8 96.6 87.4 108.2
95CI 95% confidence interval
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mutations were especially clustered in poorly differentiated
regions with KRAS mutations or ALK translocation [27].
The gene mutation landscape is a new dimension with a lot
of potential prognostic markers. These factors may explain
that the growing proportion of favourable or unfavourable
histological component is not necessarily followed by better
or poorer prognosis. The gene mutations cannot be predicted
by using only morphological parameters; therefore, the mo-
lecular studies have inevitable role for clinical management
and therapy. Parallel phylogenetic studies of differentmorpho-
logical patterns of the same tumour could help clarifying how
these patterns could correspond to genetic alterations.
The prognostic impact of predominant growth pattern was
proven on the basis of measuring the area occupied by each
pattern on all available (and digitalized) slides, i.e. the most
precise way of determining the size of each component from
the material available. We think that the study is unique in this
respect . Tumours with a secondary predominant
micropapillary component demonstrated significant differ-
ences in OS and DFS from micropapillary predominant tu-
mours and non-micropapillary tumours. Therefore, we sug-
gest using predominant and secondly predominant patterns
particularly in tumours having solid (as suggested by others
[12, 18, 21]) or micropapillary (as proven by our data)
patterns.
As concerns reproducibility, the reproducibility of the nov-
el WHO classification was proven by several studies [32, 33],
but to our knowledge, this is the first study where all tumour-
containing slides were digitalized, annotated (Fig. 1), and the
area involved by each pattern was objectively calculated to be
compared with the proportions gained by naked eye estima-
tion. The statistical analysis revealed that there was no
significant difference between these two methods; therefore,
naked eye estimation of proportions can be viewed as a useful,
time-sparing method of evaluation instead of the objective,
but time-consuming, area measurement. The statistical analy-
sis pointed out that the differences in intra-observer variability
were low in most patterns evaluated. The strongest congruen-
cy was seen in cases of lepidic and solid patterns, while the
weakest congruency was observed in papillary and
micropapillary components.
Concerning the limitations of the study, elastic staining has
been proposed to better delineate the alveolar structures, but
was not performed in this study. Lepidic, acinar and papillary
growth may have low interobserver reproducibility without
this adjunct method. In a previous work, growth patterns of
these cases were estimated on glass slides with elastic staining
if necessary [7], and the concordance between the estimation
results of naked eye and digitalized slide analysis was high.
Another limitation is that only stage I adenocarcinomas have
been included. In higher stages, the impact of growth patterns
is controversial [34, 35], and this is why we have limited our
study to early-stage tumours.
In summary, by using the best approximation of the areas
occupied by different morphological patterns, we have con-
firmed that lepidic predominant stage I adenocarcinomas have
a good prognosis and solid or micropapillary predominant
ones have the worst prognosis. A secondly predominant com-
ponent of the bad prognostic patterns also worsen prognosis;
therefore, the reporting of all patterns observed beyond the
predominant component is recommended. Naked eye estima-
tion of the proportions of each pattern does not seem to be
worse than objective measurement on digitised slides and can
be used instead in routine practice.
Table 5 Recent studies on micropapillary (M) and solid (S) patterns as non-predominant components (OS overall survival,DFS disease-free survival,
CIR cumulative incidence of recurrence)
Author Journal Year Number Stage Follow-up Pattern Cut off
Miyoshi et al. [14] Am J Surg Pathol 2003 154 I OS M > 5%
Makimoto et al. [24] Histopathology 2004 85 I OS M > 10%
Mora- Sanchez et al. [15] Hum Pathol 2008 92 I OS M > 5%
Kamiya et al. [10] Mod Pathol 2008 197 IA OS M > 1%
Nagano et al. [11] Lung Cancer 2010 156 I OS M > 1%
Yeh et al. [16] J Clin Pathol 2012 176 I DFS M > 5%
Sumiyoshi et al. [20] Lung Cancer 2013 256 IA OS/DFS M > 5%
Nitadori et al. [5] J Natl Cancer Inst 2013 734 IA (< 2 cm) CIR M > 5%
Koga et al. [28] Lung Cancer 2013 99 IA OS M > 10%
Cha et al. [12] J Thorac Cardiovasc Surg 2014 511 IA (< 3 cm) OS/DFS M/S 1 %
Zhao et al. [21] Lung Cancer 2015 201 IA (< 3 cm) OS/DFS M/S Second predominant
Tsubokawa et al. [17] Eur J Cardiothorac Surg 2016 347 IA DFS M > 5%
Yanagawa et al. [18] J Thorac Oncol 2016 420 I OS/DFS M/S > 5%
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